RNAIII inhibiting peptide suppresses the adhesion of staphylococcus epidermis on the Hela cells

doi:10.3969/j.issn.2095-4344.2014.44.024

Abstract

Abstract:

BACKGROUND: Staphylococcal infections and its biofilm formation can occur when orthopedic implants or wound is healing, and are regulated by bacterial population sensing mechanism. RNAIII inhibiting peptide intervenes the quorum-sensing system of staphylococcal and blocks the signal transduction among staphylococcal cells, and inhibits staphylococcal biofilm formation, and then prevents staphylococcal infections.
OBJECTIVE: To investigate the influence of RNAIII inhibiting peptide on the adhesion of staphylococcus epidermis to the Hela cells.
METHODS: The Hela cells were cultured in vitro. There were four groups in this study. In the blank group, saline with dimethyl sulfoxide was added in each well. In the RNAIII inhibiting peptide group, dimethyl sulfoxide solution containing RNAIII inhibiting peptide was added. In the levofloxacin group, levofloxacin was added. In the combination group, the dose was in accordance with above methods. Using intergroup control method, the adhesion of staphylococcus epidermis to the Hela cells was compared under the effects of saline, RNAIII inhibiting peptide and levofloxacin and their combination.
RESULTS AND CONCLUSION: In the blank group, abundant bacterial adhered to Hela cells. The number of adhered bacteria was significantly lower in each medicine group than in the blank group (P < 0.001). The spot count was significantly lower in the levofloxacin group than in the RNAIII inhibiting peptide group (P < 0.05). In the combination group, the number of bacteria adhered to Hela cells was decreased (P < 0.01). Results verified that RNAIII inhibiting peptide effectively suppressed the adhesion of staphylococcus epidermis to the host cells, and showed synergistic effects on antibiotics.

中国组织工程研究杂志出版内容重点：人工关节；骨植入物；脊柱；骨折；内固定；数字化骨科；组织工程

全文链接：

Key words: tissue engineering, bacteria, infection, RNA, staphylococcus

CLC Number:

R318

Xing Qing-chang, Hao Li-bo, Wang Ji-fang. RNAIII inhibiting peptide suppresses the adhesion of staphylococcus epidermis on the Hela cells[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(44): 7183-7187.

Figures/Tables 3

References

[1]Patterson JL, Stull-Lane A, Girerd PH, et al. Analysis of adherence, biofilm formation and cytotoxicity suggests a greater virulence potential of Gardnerella vaginalis relative to other bacterialvaginosis-associated anaerobes. Microbiology. 2010;156(2):392-399.
[2]Kjelleberg S, Molin S. Is there a role for quorom sensing signals in bacterial biofilm? Current Opin Microb 2002;5: 254-258.
[3]Dunne WM. Bacterial adhesion: seen any good biofilms lately? Clin Microbiol Rev. 2002;15:55-66.
[4]Gov Y, Bitler A, Dell'Acqua G, et al. RNAⅢ inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: strucure and function analysis. Peptides. 2001; 22(10): 1609-1620.
[5]Balaban N, Giacometti A, Cirioni O. Use of the quorum-sensing inhibitor RNAⅢ-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis. 2003;187(4):625-630.
[6]邢庆昌,郝立波,王继芳.固相合成法合成葡萄球菌RNAⅢ抑制肽的鉴定[J].中国组织工程研究与临床康复,2009,13(13): 2419-2422.
[7]Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-532.
[8]Giacometti A, Cirioni O, Gov Y, et al. RNA Ⅲ inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003; 47(6):1979-1983.
[9]Balaban N, Giacometti A, Cirioni O. Use of the quorum-sensing inhibitor RNAⅢ-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis. 2003;187(4):625-630.
[10]Vieira-da-Motta O, Ribeiro PD, Dias da Silva W, et al. RNAⅢ inhibiting peptide (RIP) inhibits agr-regulated toxin production. Peptides. 2001;22(10):1621-1627.
[11]邢庆昌,郝立波,王继芳.应用RNAⅢ抑制肽( RIP)抑制葡萄球菌毒素产生的实验研究[J].科学技术与工程,2011,11(2):317- 320.
[12]Yang G, Cheng H, Liu C, et al. Inhibition of Staphylococcus aureus pathogenesis in vitro and in vivo by RAP-binding peptides. Peptides. 2003;24(11):1823-1828.
[13]Dell'Acqua G, Giacometti A, Cirioni O, et al. Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAⅢ-inhibiting peptide. J Infect Dis. 2004;190(2):318-320.
[14]Balaban N, Gov Y, Giacometti A, et al. A chimeric peptide composed of a dermaseptin derivative and an RNA Ⅲ-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. Antimicrob Agents Chemother. 2004; 48(7):2544-2550.
[15]郝立波,邢庆昌,王继芳,等.RNAⅢ抑制肽抑制葡萄球菌在人工关节材料表面黏附的实验研究[J].中国矫形外科杂志,2008,16(23): 1814-1817.
[16]Balaban N, Singh B, Goldkorn RT, et al. Activation and inhibition of the staphylococcal agr system. Technical comment: Response. Science. 2000;287-391.
[17]Gustafsson E, Nilsson P, Karlsson S, et al. Characterizing the Dynamics of the Quorum-Sensing System in Staphylococcus aureus. J Mol Microbiol Biotechnol. 2004; 8(4):232-242.
[18]Park MK, Park JS, Park EM, et al. Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis.Arthritis Rheumatol. 2014;66(5): 1195-207.
[19]Lee J, Park DY, Park do Y, et al. Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage. Invest Ophthalmol Vis Sci. 2014;55(4):2191-2199.
[20]Ariyoshi W, Okinaga T, Knudson CB, et al. High molecular weight hyaluronic acid regulates osteoclast formation by inhibiting receptor activator of NF-κB ligand through Rho kinase. Osteoarthritis Cartilage. 2014;22(1):111-120.
[21]Hamm A, Veschini L, Takeda Y, et al. PHD2 regulates arteriogenic macrophages through TIE2 signalling. EMBO Mol Med. 2013;5(6):843-857.
[22]Naidu VG, Dinesh Babu KR, et al. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines. Chem Biol Interact. 2013;203(2): 467-479.
[23]Rodrigues WF, Madeira MF, da Silva TA, et al. Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation. Br J Pharmacol. 2012;165(7):2140-2151.
[24]Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets. 2011;12(2):173-181.
[25]Lee YS, Kim YS, Lee SY, et al. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone. 2010;47(5):926-937.
[26]Levitin A, Yanofsky C. Positions of Trp codons in the leader peptide-coding region of the at operon influence anti-trap synthesis and trp operon expression in Bacillus licheniformis. J Bacteriol. 2010;192(6):1518-1526.
[27]Bandhakavi S, Kim YM, Ro SH, et al. Quantitative nuclear proteomics identifies mTOR regulation of DNA damage response. Mol Cell Proteomics. 2010;9(2):403-414.
[28]Yu M, Moreno JL, Stains JP, et al. Complex regulation of tartrate-resistant acid phosphatase (TRAP) expression by interleukin 4 (IL-4): IL-4 indirectly suppresses receptor activator of NF-kappaB ligand (RANKL)-mediated TRAP expression but modestly induces its expression directly. J Biol Chem. 2009;284(47):32968-32979.
[29]Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009;18(5):637-646.
[30]Geng W, Hill K, Zerwekh JE, et al. Inhibition of osteoclast formation and function by bicarbonate: role of soluble adenylyl cyclase. J Cell Physiol. 2009;220(2):332-240.
[31]Burton JB, Priceman SJ, Sung JL, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008;68(19): 7828-7837.
[32]Ma WW, Jimeno A. Strategies for suppressing angiogenesis in gynecological cancers.Drugs Today (Barc). 2007;43(4): 259-273.
[33]Balaban N, Cirioni O, Giacometti A, et al. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother. 2007;51(6):2226-2229.
[34]Kim K, Kim JH, Lee J, et al. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood. 2007; 109(8):3253-3259.
[35]Christensen EN, Mendelsohn ME. Cyclic GMP-dependent protein kinase Ialpha inhibits thrombin receptor-mediated calcium mobilization in vascular smooth muscle cells.J Biol Chem. 2006;281(13):8409-8416.
[36]Bundschu K, Gattenlöhner S, Knobeloch KP, et al. Tissue-specific Spred-2 promoter activity characterized by a gene trap approach. Gene Expr Patterns. 2006;6(3):247-255.
[37]Murray JL, Mavrakis M, McDonald NJ, et al. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J Virol. 2005;79(18): 11742-11751.
[38]Mangashetti LS, Khapli SM, Wani MR. IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling. J Immunol. 2005;175(2): 917-925.
[39]Mei ZZ, Zheng XF, Dong Y, et al. Inhibiting expression of human telomerase reverse transcriptase promotes degradation of survivin protein. Ai Zheng. 2005;24(5): 525-530.
[40]Hu ZW, Shen ZY, Huang JH. Experimental study on effect of epimedium flavonoids in protecting telomere length of senescence cells HU. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004;24(12):1094-1097.
[41]Biswas SK, McClure D, Jimenez LA, et al. Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. Antioxid Redox Signal. 2005;7(1-2):32-41.
[42]Yanofsky C. The different roles of tryptophan transfer RNA in regulating trp operon expression in E. coli versus B. subtilis. Trends Genet. 2004;20(8):367-374.
[43]Chen G, Yanofsky C. Features of a leader peptide coding region that regulate translation initiation for the anti-TRAP protein of B. subtilis. Mol Cell. 2004;13(5):703-711.
[44]Oh KO, Kim SW, Kim JY, et al. Effect of Rehmannia glutinosa Libosch extracts on bone metabolism. Clin Chim Acta. 2003; 334(1-2):185-195.
[45]Wulff C, Wilson H, Rudge JS, et al. Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap (A40). J Clin Endocrinol Metab. 2001;86(7):3377-3386.
[46]Balaban N, Goldkorn T, Gov Y, et al. Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating Protein (TRAP). J Biol Chem. 2001;276(4): 2658-2667.
[47]Laitala-Leinonen T, Löwik C, Papapoulos S, et al. Inhibition of intravacuolar acidification by antisense RNA decreases osteoclast differentiation and bone resorption in vitro. J Cell Sci. 1999;112( Pt 21):3657-3666.